Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Genentech Rituxan Sales Level Off; Manufacturing Issues Resolved

  • News

Executive Summary

Sales of Genentech's Rituxan appear to be leveling off as the product approaches full penetration in its largest markets

You may also be interested in...



Genentech Rituxan Promotions Under Investigation By DoJ

Genentech is responding to a subpoena regarding its promotions of the oncologic agent Rituxan

Genentech Avastin Account Orders Double, Reorder Rate Improves To 80%

Eighty percent of Genentech's accounts are currently placing reorders for the colorectal cancer therapy Avastin

Genentech Rituxan Sales Dip On Medicare Rate Cut; Demand “Still Strong”

Rituxan sales appear to have stabilized following a brief dip in January related to changes in Medicare Part B reimbursement for the oncologic, Genentech told investors April 8

Table

View full table

Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS044802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By